10-Q: Avid Bioservices Reports 32% Revenue Increase in Second Quarter Amidst Pending Merger

Avid Bioservices saw a 32% increase in revenue for the second fiscal quarter, reaching $33.5 million, while also announcing a pending merger agreement.

Summary

• Avid Bioservices reported a 32% increase in revenue for the three months ended October 31, 2024, reaching $33.5 million compared to $25.4 million in the same period last year.
• The company's manufacturing revenues increased to $27.3 million, up from $20.1 million, and process development revenues rose to $6.2 million from $5.3 million.
• The gross loss decreased to $2.0 million from $4.7 million year-over-year, primarily due to increased revenues.
• Selling, general, and administrative expenses increased to $10.6 million from $6.6 million, driven by higher compensation and legal fees.
• The operating loss was $12.6 million, compared to $11.2 million in the prior year.
• Interest expense increased significantly to $3.3 million from $0.8 million due to new convertible senior notes.
• The net loss was $17.4 million, compared to $9.5 million in the same period last year.
• The company's backlog increased to approximately $220 million from $199 million at the end of the same quarter in fiscal 2024.
• A merger agreement was entered into on November 6, 2024, with Space Finco, Inc. and Space Mergerco, Inc., with Avid Bioservices to become a wholly-owned subsidiary of Parent.

Sentiment

Score: 5

Explanation: The document presents mixed signals. While revenue growth is strong and backlog is increasing, the company is still operating at a loss and expenses are rising. The pending merger adds uncertainty. Overall, the sentiment is neutral to slightly negative.

Positives

• The company experienced a significant 32% increase in revenue, indicating strong demand for its services.
• The backlog increased to $220 million, suggesting future revenue growth.
• The gross loss decreased, showing improved operational efficiency.
• Manufacturing and process development revenues both saw substantial growth.

Negatives

• The company reported a net loss of $17.4 million for the quarter.
• Selling, general, and administrative expenses increased significantly by 61%.
• Interest expense increased substantially due to new debt.
• The operating loss increased year-over-year.

Risks

• The pending merger introduces uncertainty and potential disruptions to the business.
• The merger agreement includes restrictions on business activities and potential termination fees.
• The company's ability to raise additional capital is restricted during the pendency of the merger.
• There is a risk that the merger may not be completed.
• The company is subject to various legal proceedings and disputes in the ordinary course of business.
• The company's backlog is subject to risks such as customer cancellations and delays.

Future Outlook

The company anticipates that a significant amount of its backlog will be recognized as revenue over the next five fiscal quarters. The company believes that its existing cash and cash equivalents on hand and its anticipated cash flows from operating activities will be sufficient to fund its operations for at least the next 12 months from the date of this Quarterly Report.

Management Comments

• The company's growth strategy seeks to align with the growth of the biopharmaceutical drug substance contract services market.
• The company aims to invest in additional capacity, capabilities, and resources to meet customer demand.
• The company intends to broaden market awareness through a diversified marketing strategy.
• The company plans to expand its customer base and programs with existing customers.
• The company will explore and invest in strategic opportunities to enhance capabilities.
• The company seeks to increase its operating profit margin to best-in-class within the industry.

Industry Context

The company operates in the contract development and manufacturing organization (CDMO) sector, which is experiencing growth due to the increasing demand for biologics manufacturing. The pending merger suggests a trend of consolidation within the industry.

Comparison to Industry Standards

• While the document does not provide specific industry benchmarks, comparable companies in the CDMO space include Catalent, Lonza, and Samsung Biologics.
• These companies often report similar metrics such as revenue growth, gross profit margins, and backlog.
• Avid's revenue growth of 32% is a positive sign, but the net loss and increased expenses need to be compared to industry averages.
• The backlog of $220 million is a key indicator of future revenue potential and should be compared to the backlogs of similar-sized CDMOs.
• The pending merger is a significant event that could change Avid's competitive position in the industry.

Stakeholder Impact

• Shareholders will be impacted by the pending merger, with each share to be converted into $12.50 in cash.
• Employees may experience uncertainty due to the merger, potentially affecting morale and retention.
• Customers may be impacted by changes in the company's operations and strategy post-merger.
• Suppliers and creditors may be affected by the company's financial performance and the merger.

Next Steps

• The company will seek stockholder approval for the merger.
• The company will work to satisfy the conditions for the merger, including regulatory approvals.
• The company will continue to execute on its backlog and manage its operations during the pendency of the merger.

Key Dates

Keywords

CDMO, contract manufacturing, biologics, revenue, merger, biopharmaceutical, process development, manufacturing, financial results, backlog